Search
forResearch 10 of 759
- PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
- Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
- Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
- A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
- Endocrine intervention for transsexuals
- Physiological and biological skin changes in pregnancy
- Complications of Rhytidectomy
- Hormonal therapies for acne
- Care Considerations and Management of Transgender Individuals After Kidney Transplantation: A Single Institution Experience and Literature Review
- Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →